Millipore Sigma Vibrant Logo

OP107 Anti-BRCA1 (Ab-4) Mouse mAb (SD118)

View Products on Sigmaaldrich.com
OP107
Visualizza prezzi e disponibilità

Panoramica

Replacement Information

Tabella delle specifiche principali

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Prezzi e disponibilità

Numero di catalogo DisponibilitàConfezionamento Qtà/conf Prezzo Quantità
OP107-100UG
Verifica della disponibilità in corso...
Disponibilità limitata
Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      Fiala di plastica 100 μg
      Ricerca del prezzo in corso...
      Non è stato possibile trovare il prezzo
      La quantità minima deve essere un multiplo di
      Maximum Quantity is
      Al termine dell'ordine Maggiori informazioni
      Lei ha salvato ()
       
      Richiedi il prezzo
      Description
      OverviewRecognizes the ~220 kDa BRCA1 protein in HBL-100 and SK-BR3 cells. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
      Catalogue NumberOP107
      Brand Family Calbiochem®
      SynonymsAnti-Breast Cancer Susceptibility Protein
      References
      ReferencesChen, J.J., et al. 1999. Cancer Res. 59, 1752s.
      Cressman, V.L., et al. 1999. Cell Growth Differ. 10, 1.
      Irminger-Finger, I., et al. 1999. Biol. Chem. 380, 117.
      Xu, X., et al. 1999. Nat. Genet. 22, 37.
      Wilson, C.A., et al. 1999. Nat. Genet. 21, 236.
      Andres, J.L., et al. 1998. Oncogene 16, 2229.
      Chen, J., et al. 1998. Mol. Cell 2, 317.
      Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
      Fan, S., et al. 1998. Int. J. Cancer 77, 600.
      Gowen, L.C., et al. 1998. Science 281, 1009.
      Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA 95, 12983.
      Shen, S.X., et al. 1998. Oncogene 17, 3115.
      Tulchin, N., et al. 1998. Int. J. Oncol. 13, 513.
      Ludwig, T., et al. 1997. Genes Dev 11, 1226.
      Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA 94, 7138.
      Scully, R., et al. 1997. Cell 90, 425.
      Thakur, S., et al. 1997. Mol. Cell Biol. 17, 444.
      Wilson, C.A., et al. 1997. Oncogene 14, 1.
      Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol. 23, 1.
      Chen, Y., et al. 1996. Cancer Res. 56, 3168.
      Liu, C.Y., et al. 1996. Genes Dev. 10, 1835.
      Gudas, J.M., et al. 1996. Cell Growth Differ. 7, 717.
      Scully, R., et al. 1996. Science 272, 123.
      Vaughn, J.P., et al. 1996. Cell Growth Differ. 7, 711.
      Wilson, C.A. et al. 1996. Nat. Genet. 13, 264.
      Thompson, M.E., et al. 1995. Nat. Genet. 9, 444.
      Miki, Y., et al. 1994. Science 266, 66.
      Product Information
      DeclarationSold under license of U.S. Patents 5,753,441 and 6,162,897.
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Positive controlHBL-100 or SK-BR3 cells
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting, Immunoprecipitation Wilson, C.A., et al. 1999. Nat. Genet. 21, 236. Original Clone Scully, R., et al. 1996. Science 272, 123.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Not Paraffin Sections
      Application NotesFrozen Sections (2 µg/ml)
      Immunoblotting (2 µg/ml, see application references)
      Immunofluorescence (2 µg/ml)
      Immunoprecipitation (2 µg, see application references)
      Paraffin Sections (not recommended)
      Application CommentsMaximal BRCA1 levels are observed in subconfluent cell populations after serum stimulation. Highly specific BRCA1 antibody useful for blotting and IP of full length BRCA1 protein. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena recombinant polypeptide corresponding to amino acids 1005-1313 in exon 11 of human BRCA1
      ImmunogenHuman
      CloneSD118
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      OP107-100UG 04055977224924

      Documentation

      Anti-BRCA1 (Ab-4) Mouse mAb (SD118) MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      Anti-BRCA1 (Ab-4) Mouse mAb (SD118) Certificati d'Analisi

      TitoloNumero di lotto
      OP107

      Riferimenti bibliografici

      Panoramica delle referenze
      Chen, J.J., et al. 1999. Cancer Res. 59, 1752s.
      Cressman, V.L., et al. 1999. Cell Growth Differ. 10, 1.
      Irminger-Finger, I., et al. 1999. Biol. Chem. 380, 117.
      Xu, X., et al. 1999. Nat. Genet. 22, 37.
      Wilson, C.A., et al. 1999. Nat. Genet. 21, 236.
      Andres, J.L., et al. 1998. Oncogene 16, 2229.
      Chen, J., et al. 1998. Mol. Cell 2, 317.
      Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
      Fan, S., et al. 1998. Int. J. Cancer 77, 600.
      Gowen, L.C., et al. 1998. Science 281, 1009.
      Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA 95, 12983.
      Shen, S.X., et al. 1998. Oncogene 17, 3115.
      Tulchin, N., et al. 1998. Int. J. Oncol. 13, 513.
      Ludwig, T., et al. 1997. Genes Dev 11, 1226.
      Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA 94, 7138.
      Scully, R., et al. 1997. Cell 90, 425.
      Thakur, S., et al. 1997. Mol. Cell Biol. 17, 444.
      Wilson, C.A., et al. 1997. Oncogene 14, 1.
      Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol. 23, 1.
      Chen, Y., et al. 1996. Cancer Res. 56, 3168.
      Liu, C.Y., et al. 1996. Genes Dev. 10, 1835.
      Gudas, J.M., et al. 1996. Cell Growth Differ. 7, 717.
      Scully, R., et al. 1996. Science 272, 123.
      Vaughn, J.P., et al. 1996. Cell Growth Differ. 7, 711.
      Wilson, C.A. et al. 1996. Nat. Genet. 13, 264.
      Thompson, M.E., et al. 1995. Nat. Genet. 9, 444.
      Miki, Y., et al. 1994. Science 266, 66.
      Scheda tecnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision02-October-2007 RFH
      SynonymsAnti-Breast Cancer Susceptibility Protein
      ApplicationFrozen Sections (2 µg/ml)
      Immunoblotting (2 µg/ml, see application references)
      Immunofluorescence (2 µg/ml)
      Immunoprecipitation (2 µg, see application references)
      Paraffin Sections (not recommended)
      DescriptionPurified mouse monoclonal antibody generated by immunizing RBF/DnJ mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~220 kDa BRCA1 protein.
      BackgroundInactivation of the BRCA1 gene is responsible for some forms of familial breast and ovarian cancer and sporadic ovarian cancer. BRCA1 encodes a protein of 1863 amino acids with an amino-terminal domain that exhibits similarity to the zinc-ring domain found in several regulatory and transcription factors. Two isoforms of BRCA1 are commonly expressed; a full length ~220 kDa protein that is predominantly nuclear and a ~120 kDa form that is missing most of exon 11. Inhibition of BRCA1 expression leads to accelerated growth of mammary cells in vitro while loss of expression is observed during progression from benign disease to metastatic breast cancer. BRCA1 undergoes cell cycle regulation, with mRNA expression induced prior to DNA synthesis, while DNA damage leads to down regulation. BRCA1 protein is also subject to post-translational modification and re-localization at various stages in the cell cycle or in response to DNA damage, and also is required for aspects of transcription-coupled DNA repair. The protein is essential for embryogenesis since mice nullizygous for BRCA1 die in utero, while heterozygosity or conditional knockout of BRCA1 leads to increased tumor formation and aberrant mammary ductal morphology. BRCA1 forms stable associations with a number of proteins including BARD1, p53, BRCA2, Rad51, RNA Pol II holoenzyme, and BAP1. Interestingly, loss of BRCA1 may increase the risk of p53 inactivation, which suggests that BRCA1 is a key element in maintenance of genome integrity.
      HostMouse
      Immunogen speciesHuman
      Immunogena recombinant polypeptide corresponding to amino acids 1005-1313 in exon 11 of human BRCA1
      CloneSD118
      IsotypeIgG₁
      Specieshuman
      Positive controlHBL-100 or SK-BR3 cells
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsMaximal BRCA1 levels are observed in subconfluent cell populations after serum stimulation. Highly specific BRCA1 antibody useful for blotting and IP of full length BRCA1 protein. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesChen, J.J., et al. 1999. Cancer Res. 59, 1752s.
      Cressman, V.L., et al. 1999. Cell Growth Differ. 10, 1.
      Irminger-Finger, I., et al. 1999. Biol. Chem. 380, 117.
      Xu, X., et al. 1999. Nat. Genet. 22, 37.
      Wilson, C.A., et al. 1999. Nat. Genet. 21, 236.
      Andres, J.L., et al. 1998. Oncogene 16, 2229.
      Chen, J., et al. 1998. Mol. Cell 2, 317.
      Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
      Fan, S., et al. 1998. Int. J. Cancer 77, 600.
      Gowen, L.C., et al. 1998. Science 281, 1009.
      Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA 95, 12983.
      Shen, S.X., et al. 1998. Oncogene 17, 3115.
      Tulchin, N., et al. 1998. Int. J. Oncol. 13, 513.
      Ludwig, T., et al. 1997. Genes Dev 11, 1226.
      Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA 94, 7138.
      Scully, R., et al. 1997. Cell 90, 425.
      Thakur, S., et al. 1997. Mol. Cell Biol. 17, 444.
      Wilson, C.A., et al. 1997. Oncogene 14, 1.
      Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol. 23, 1.
      Chen, Y., et al. 1996. Cancer Res. 56, 3168.
      Liu, C.Y., et al. 1996. Genes Dev. 10, 1835.
      Gudas, J.M., et al. 1996. Cell Growth Differ. 7, 717.
      Scully, R., et al. 1996. Science 272, 123.
      Vaughn, J.P., et al. 1996. Cell Growth Differ. 7, 711.
      Wilson, C.A. et al. 1996. Nat. Genet. 13, 264.
      Thompson, M.E., et al. 1995. Nat. Genet. 9, 444.
      Miki, Y., et al. 1994. Science 266, 66.
      Application referencesImmunoblotting, Immunoprecipitation Wilson, C.A., et al. 1999. Nat. Genet. 21, 236. Original Clone Scully, R., et al. 1996. Science 272, 123.